论文部分内容阅读
目的:对使用美托洛尔或卡维地洛治疗慢性心力衰竭的临床疗效和安全性进行探讨和分析。方法:在为2009年12月至2011年12月我院收治的82例慢性心力衰竭患者进行治疗的过程中,将他们平均分成两组,为对照组患者使用美托洛尔进行治疗,为观察组患者使用卡维地洛进行治疗,对两组患者治疗前后心功能指标及治疗后的临床疗效进行观察比较,并记录用药过程中两组患者发生的不良反应。结果:通过比较发现,两组患者经用药治疗后其心率、LVDd、LVDs和LVEF得到明显改善,与治疗前相比差异具有统计学意义(p<0.05),但组间心动图指标比较差异不明显(p>0.05)。观察组患者的治疗总有效率为97.56%,明显高于对照组的治疗总有效率(82.93%)。在观察组患者中,有3例患者出现不良反应。在对照组患者中,有7例患者出现不良反应。两组患者治疗的有效率和发生不良反应的几率相比较,差异显著,具有统计学意义(p<0.05)。结论:美托洛尔和卡维地洛均可改善慢性心力衰竭患者的心功能,但后者的疗效明显好于前者,而且具有安全可靠的特点,值得在临床上推广应用。
Objective: To investigate and analyze the clinical efficacy and safety of metoprolol or carvedilol in the treatment of chronic heart failure. Methods: During the treatment of 82 patients with chronic heart failure treated in our hospital from December 2009 to December 2011, they were divided equally into two groups, and the patients in the control group were treated with metoprolol for observation. The patients in the group were treated with carvedilol. The cardiac function indexes before and after treatment and the clinical effect after treatment were observed and compared, and the adverse reactions in both groups were recorded. Results: By comparison, the heart rate, LVDd, LVDs and LVEF of the two groups were significantly improved after treatment (P <0.05), but there was no significant difference between the two groups Significantly (p> 0.05). The total effective rate of observation group was 97.56%, which was significantly higher than that of control group (82.93%). In the observation group of patients, 3 patients showed adverse reactions. In the control group, 7 patients developed adverse reactions. There was significant difference between the two groups in the treatment efficiency and the incidence of adverse reactions, with statistical significance (p <0.05). Conclusion: Both metoprolol and carvedilol can improve cardiac function in patients with chronic heart failure, but the latter is significantly better than the former, and it is safe and reliable, which is worthy of clinical application.